» Authors » Fernando Anjos-Afonso

Fernando Anjos-Afonso

Explore the profile of Fernando Anjos-Afonso including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 1452
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hinchly T, Bonnet D, Anjos-Afonso F
Exp Hematol . 2025 Feb; 144:104729. PMID: 39892848
Recently, human CD34 hematopoietic stem cells (HSCs) have been purified to a frequency of approximately one in three cells, a population denoted as CD34CD38CD45RACD90 endothelial protein C receptor (EPCR) HSCs....
2.
Mian S, Ariza-McNaughton L, Anjos-Afonso F, Guring R, Jackson S, Kizilors A, et al.
Hemasphere . 2024 May; 8(5):e80. PMID: 38774656
Immunodeficient mouse models are widely used for the assessment of human normal and leukemic stem cells. Despite the advancements over the years, reproducibility, as well as the differences in the...
3.
Anjos-Afonso F, Bonnet D
Blood . 2023 Apr; 142(6):509-518. PMID: 37018661
The ability to isolate and characterize different hematopoietic stem cell (HSC) or progenitor cell populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis, and regeneration as well...
4.
Anjos-Afonso F, Buettner F, Mian S, Rhys H, Perez-Lloret J, Garcia-Albornoz M, et al.
Nat Commun . 2022 Apr; 13(1):2048. PMID: 35440586
The heterogeneous nature of human CD34 hematopoietic stem cells (HSCs) has hampered our understanding of the cellular and molecular trajectories that HSCs navigate during lineage commitment. Using various platforms including...
5.
Mian S, Anjos-Afonso F, Bonnet D
Front Immunol . 2021 Feb; 11:619236. PMID: 33603749
Immunotherapy has established itself as a promising tool for cancer treatment. There are many challenges that remain including lack of targets and some patients across various cancers who have not...
6.
Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, et al.
Leukemia . 2020 Feb; 34(7):1973. PMID: 32005921
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
7.
Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, et al.
Leukemia . 2019 Nov; 34(6):1658-1668. PMID: 31776464
Juvenile myelomonocytic leukemia (JMML) is a rare aggressive myelodysplastic/myeloproliferative neoplasm of early childhood, initiated by RAS-activating mutations. Genomic analyses have recently described JMML mutational landscape; however, the nature of JMML-propagating...
8.
Menendez-Gonzalez J, Vukovic M, Abdelfattah A, Saleh L, Almotiri A, Thomas L, et al.
Stem Cell Reports . 2019 Aug; 13(2):291-306. PMID: 31378673
Subversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia (AML). Using a...
9.
Lopez-Millan B, de la Guardia R, Roca-Ho H, Anguita E, Islam A, Romero-Moya D, et al.
Oncoimmunology . 2018 Sep; 7(9):e1477460. PMID: 30228947
Treatment for acute myeloid leukemia (AML) remains suboptimal and many patients remain refractory or relapse upon standard chemotherapy based on nucleoside analogs plus anthracyclines. The crosstalk between AML cells and...
10.
Lampreia F, Carmelo J, Anjos-Afonso F
Curr Stem Cell Rep . 2017 Aug; 3(3):202-209. PMID: 28845387
Purpose Of Review: Understanding the signaling pathways that govern hematopoietic stem and progenitor cells (HSPCs) is fundamental to uncover their regulation and how this is skewed in hematological malignancies. Whether...